Kadant Inc. — Form 10-Q Summary
Reporting period: Three months ended April 2, 2022, compared with the three months ended April 3, 2021. The request metadata says “2021 Q1,” but the filing is for Q1 2022.
Business context
Kadant supplies engineered technologies and systems for industrial processing, organized into Flow Control, Industrial Processing, and Material Handling. Its products support process efficiency and resource use. The company reported record quarterly bookings of $266.1 million and record backlog of $348.3 million; bookings included $22.4 million attributable to acquisitions.
Financial results
| Metric | Q1 2022 | Q1 2021 | Change / context |
|---|---|---|---|
| Revenue | $226.5 million | $172.5 million | Up 31%; organic revenue up 22% |
| Gross profit margin | 43.4% | 43.9% | Down 0.5 percentage points |
| Operating income | $56.0 million | $23.4 million | Includes $20.2 million gain on facility sale in 2022 |
| Adjusted operating income | $37.1 million | $24.8 million | Non-GAAP |
| Net income attributable to Kadant | $41.2 million | $16.6 million | 2022 includes the facility-sale gain |
| Diluted EPS | $3.53 | $1.43 | 2022 includes the facility-sale gain |
| Adjusted EBITDA / margin | $45.8 million / 20.2% | $32.4 million / 18.8% | Non-GAAP |
| Operating cash flow | $23.8 million | $19.1 million | Free cash flow was $20.9 million vs. $16.8 million |
Revenue grew across all segments: Flow Control $85.8 million (up 35%), Industrial Processing $93.1 million (up 35%), and Material Handling $47.6 million (up 20%). Organic growth was strongest in Industrial Processing, up 36%; Flow Control rose 18% and Material Handling 4%. Acquisitions contributed $20.0 million of consolidated revenue, while currency translation reduced revenue by $3.9 million.
Liquidity, debt and cash flows
- Cash and cash equivalents were $86.2 million at quarter-end, down from $91.2 million at January 1, 2022. Working capital was $174.7 million, compared with $162.4 million.
- Total short- and long-term obligations were $247.9 million, including $229.5 million outstanding on the revolving facility. Available facility capacity was approximately $170.0 million, plus a $150.0 million uncommitted incremental facility. The company reported a 1.16 leverage ratio and compliance with debt covenants.
- Operating cash flow was partly offset by working-capital investment: accounts receivable and inventory used $18.5 million, while accounts payable and customer deposits provided $12.2 million. Investing activities used $1.3 million; financing activities used $27.0 million, primarily reflecting debt repayments.
- The company paid $2.9 million in dividends during the quarter and declared a $0.26-per-share quarterly dividend. No shares had been repurchased under the $20 million authorization as of the filing.
Material changes and unusual items
- Reported earnings benefited materially from the $20.2 million pretax gain on the sale of a Chinese manufacturing building and land-use rights. The gain was $15.1 million after deferred taxes. A $16.1 million receivable represents the present value of remaining proceeds, due when the government sells the property or within two years of the agreements’ effective date.
- The company recorded $0.2 million of impairment charges for assets not being moved to the replacement facility. It expects approximately $20 million of total construction capital spending for the new facility over two years, including about $12 million in 2022; proceeds from the existing facility sale are expected to offset the cost.
- Gross margin declined due to mix, including a lower proportion of higher-margin parts and consumables, and lower-margin capital equipment at the Chinese stock-preparation business. Acquisitions affected segment margins in both directions.
- Debt declined from $269.5 million at year-end to $247.9 million at quarter-end. The revolving credit facility matures December 14, 2023; management said it expects to renew it before maturity.
Outlook, management commentary and risks
Management cited record bookings and backlog, continued strong demand, and positive business fundamentals, while expecting a challenging operating environment. It provided no specific revenue or earnings guidance in the supplied filing text. Planned capital expenditures are approximately $15 million for the remainder of 2022, in addition to the Chinese facility project. Management believes cash, operating cash flow, borrowing capacity, and debt-market access will be sufficient for the next 12 months and foreseeable future.
- Labor availability and supply-chain constraints are causing longer lead times, material-cost inflation, and higher freight costs. The company is using advance raw-material purchases and price adjustments where possible.
- Management highlighted COVID-19 risks, including China’s zero-COVID policy and possible facility closures, as well as customer delays or cancellations of capital projects.
- International exposure creates foreign-exchange, tariff, trade-policy, and geopolitical risks. The filing discusses Russia-Ukraine-related uncertainty and notes 2021 sales to Russia of $10.7 million, or 1% of revenue.
- Chinese bank acceptance drafts transferred to vendors were subject to customary recourse provisions in the amount of $8.4 million at quarter-end. The company said historically these drafts settled at maturity without recourse claims.
- Ordinary-course litigation is disclosed; the filing does not provide a clear quantified estimate of potential losses.
- Management concluded disclosure controls and procedures were effective, and reported no material change in internal control over financial reporting during the quarter.
Investor verification priorities
- Separate underlying operating performance from the $20.2 million facility-sale gain; review adjusted measures alongside GAAP results.
- Track collection and timing of the $16.1 million sale-proceeds receivable and progress, cost, and timing of the replacement facility.
- Assess whether record backlog converts to revenue as expected amid supply-chain, labor, and China-related disruption risks.
- Monitor organic growth and margins by segment, especially the effects of acquisition integration, product mix, and input-cost recovery through pricing.
- Verify debt-facility renewal progress before the December 2023 maturity and monitor borrowing capacity and covenant headroom.